Table 1.
Clinical characteristics of patients, number and percentage of the MM stages according to the American Joint Committee on Cancer (AJCC), tumour thickness (mm) and performed sentinel lymph node biopsies (SLNB) together with the number and proportion of positively detected sentinel lymph nodes
| Year | P‐value | |||
|---|---|---|---|---|
| 2019 | 2020 | 2021 | ||
| Median (IQR) | Median (IQR) | Median (IQR) | ||
| Tumour thickness (mm) | 0.9 (0.4–2.1) | 0.9 (0.5–1.8) | 0.9 (0.4–1.9) | 0.178 |
| Age (year) | 65 (51.2–75) | 63 (50–76) | 65 (55–77) | 0.174 |
| Year | P‐value | ||||
|---|---|---|---|---|---|
| 2019 | 2020 | 2021 | |||
| n (%) | n (%) | n (%) | |||
| Total number of newly diagnosed MM | 320 | 319 | 347 | ||
| Number of surgically treated MM cases in inpatient setting | 338 | 298 | 326 | ||
| AJCC stage | 0 (in situ) | 55 (17.2) | 41 (12.9) | 54 (15.5) | 0.529 |
| I | 185 (57.8) | 196 (61.4) | 206 (59.4) | ||
| II | 55 (17.2) | 47 (14.7) | 50 (14.4) | ||
| III | 19 (5.9) | 29 (9.1) | 26 (7.5) | ||
| IV | 6 (1.9%) | 6 (1.9) | 11 (3.2) | ||
| Tumour thickness (mm) | ≤1 | 147 (45.9) | 156 (48.9) | 163 (47.0) | 0.639 |
| >1–2 | 51 (15.9) | 61 (19.1) | 57 (16.4) | ||
| >2–4 | 32 (10.0) | 36 (11.3) | 42 (12.1) | ||
| >4 | 35 (10.9) | 25 (7.8) | 31 (9.0) | ||
| Performed SLNB | 106 (33.1) | 102 (32.0) | 110 (31.7) | 0.591 | |
| Positive SLNB | 10 (9.4 † ) | 20 (19.6†)* | 20 (18.2†)* | 0.037 | |
†
Percentage of the positive detected sentinel lymph nodes from the performed SLNB.
*
Statistically significant increase compared to the year 2019.